GlassScriptPhysician profile
Morgan Duke
NPI 1093280331
$3,750.14
in general payments reported to CMS, 2019-2025
28 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $691 · 2023: $492 · 2024: $993 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,156.70 | 2021-2025 | |
| Pfizer INC. | $359.72 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $307.52 | 2021-2025 | Nuplazid |
| Biogen, INC. | $272.95 | 2021-2025 | Tysabri, Vumerity, Leqembi |
| Biohaven Pharmaceutical Holding Company LTD. | $224.65 | 2022 | |
| Ucb, INC. | $159.72 | 2023-2024 | Briviact |
| Amgen INC. | $136.00 | 2021-2024 | Aimovig, Uplizna |
| Novartis Pharmaceuticals Corporation | $126.65 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $88.59 | 2021 | |
| Horizon Therapeutics Plc | $85.90 | 2021-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $85.25 | 2022-2023 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $85.14 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $84.62 | 2023-2024 | |
| Axsome Therapeutics, INC. | $82.23 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $67.59 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $66.28 | 2022 | |
| Eisai INC. | $49.67 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $48.22 | 2024 | Ultomiris |
| Argenx US, INC. | $41.42 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $40.71 | 2022-2024 | |
| Celgene Corporation | $38.36 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $31.54 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $27.55 | 2023 | |
| Neurelis, INC. | $20.88 | 2023 | Valtoco |
| Kyowa Kirin, INC. | $17.62 | 2023 | Nourianz |
| Avion Pharmaceuticals | $16.89 | 2022 | |
| Sk Life Science, INC. | $16.04 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.